In a move aimed at reducing doctors' reliance on opioid painkillers, the makers of a new, opioid-free inhalable pain reliever have launched a campaign to market the drug to more than 9,000 women’s healthcare providers across the U.S. this fall.
SPRIX Nasal Spray, a joint product of Egalet Corp. and Ascend Therapeutics , is a non-steroidal anti-inflammatory pain medication ideal for tough pain that ordinarily would be prescribed an opioid-based drug like hydrocodone or oxycodone. It can be used for up to five days, and has no addiction risk.
Ascend’s 37-member salesforce will emphasize SPRIX in sales calls to doctors treating women’s medical issues, offering an alternative to opioids, the abuse of which has caused a national health crisis.
“SPRIX offers an attractive product profile as anon-narcotic that provides opioid-level pain relief for our target women's healthcare providers," said Sunil Sehgal, chief executive officer at Ascend. "Having now been trained on SPRIX Nasal Spray, our representatives are out educating their target HCPs about the benefits and risks of the product."